October 30, 2019   General

Arlington, MA – October 30, 2019 – Third Pole Therapeutics, a privately held company developing and delivering transformative life-saving cardio-pulmonary therapies, has named seasoned healthcare executive Bill Athenson as its new Chief Executive Officer.

More >>

  August 21, 2019   Press Release

Newest Patents Cover Nitric Oxide Generation and Wearable Delivery Systems Arlington, MA – August 21, 2019 – Third Pole Therapeutics, a privately held company developing and delivering transformative life-saving cardio-pulmonary therapies, announced today that the U.S. Patent and Trademark Office has recently issued U.S. patents covering Third Pole’s innovative general and portable inhaled Nitric Oxide (iNO) delivery systems. >> Read …

  July 19, 2019   In the News

Each year, roughly 100,000 babies worldwide are diagnosed with a life-threatening condition called persistent pulmonary hypertension of the newborn (PPHN). In infants with PPHN, blood does not circulate properly through the lungs, and sufficient oxygen does not reach the heart, brain and other major organs. Yet, despite the proven effectiveness of inhaled nitric oxide (iNO) as a life-saving treatment for PPHN, access to it by patients has been severely limited—in part because of its expensive, unwieldy system of delivery…

  July 1, 2017   Warning

Notice: Following the links below you may be leaving Third Pole Inc.’s website. Third Pole does not imply its endorsement of or concurrence with such information, conclusions or recommendations.

Promising Prototypes to Watch in 2018

Engineering for Change

  December 29, 2017   In the News

The technologies that improve lives in the world’s underserved communities are born as prototypes that evolve through testing and tinkering in workshops, laboratories and garages…

  October 15, 2017   In the News

A new device, the Third Pole is able to generate nitric oxide (NO) from the air that can help improve oxygenation and treat pulmonary hypertension a common problem among some newborns…

  June 7, 2017   In the News

Inhaled nitric oxide (iNO) relaxes blood vessels in the lungs and is an important and life-saving treatment for pulmonary hypertension. Current iNO delivery solutions are estimated to cost $2,800 per day and rely on compressed gas delivery which limits accessibility and applicability of this technology worldwide…

  May 1, 2014   In the News

In the 25 years since discovering a life-saving therapy consisting of breathing low levels of the gas nitric oxide—which is still the only selective inhaled pulmonary vasodilator—Massachusetts General Hospital (MGH) anesthesiologist Warren M. Zapol, MD, and his MGH team has given clinicians a treatment to simply save the lives of vast numbers of hypoxic newborns (“blue babies”)and prevent or reverse pulmonary hypertension in hundreds of thousands of adults during surgery…